We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
TET Systems and Novo Nordisk Sign License Agreement
News

TET Systems and Novo Nordisk Sign License Agreement

TET Systems and Novo Nordisk Sign License Agreement
News

TET Systems and Novo Nordisk Sign License Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TET Systems and Novo Nordisk Sign License Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TET Systems Holding GmbH & Co. KG announced that TET Systems and Novo Nordisk A/S have signed a license agreement allowing the Hagedorn Research Institute (HRI), a research institute within Novo Nordisk A/S, the use of the Tet Technology for its internal research activities.

TET Systems was founded by Prof. Dr. H. Bujard and his colleagues. According to TET Systems, its technology is the most widely used method to control gene expression in higher organisms. 85% of the world's leading pharmaceutical companies license the Tet Technology for their internal R&D activities. The broad usage of the Tet Technology is demonstrated by more than 6,200 publications in peer-reviewed journals (June 2009).

“We are very glad that we can add the Hagedorn Research Institute as part of Novo Nordisk, one of the premier global pharmaceutical companies with European headquarters, to our growing list of licensees”, stated Dr. E. Bohnlein, CEO of TET Systems.

“This license agreement again shows that the Tet Technology provides a clear technological advantage to innovative biomedical research which translates into a strategic advantage for these pharmaceutical and biotech companies.”
Advertisement